In 2023, PQA launched a multiphase national medication therapy management (MTM) initiative to address stakeholder needs and advance MTM quality measurement. PQA has identified six objectives that can advance MTM quality and measurement, and the MTM Advisory Group is serving as a forum providing expert feedback on how to approach these.
The evolution of PQA’s continued involvement in medication therapy management (MTM) spans over a decade. Milestones include endorsement of the Completion Rate for Comprehensive Medication Review performance measure in 2011 and development of the foundational Medication Therapy Problem Categories Framework in 2017.
PQA is now accepting self-nominations for the Diversity in Quality Scholarship. The program provides scholarships for health care professional students to attend the 2025 PQA Annual Meeting, May 19-21, in Tampa, Fla., and participate in the pre-meeting Medication Use Quality Live workshop on May 19.
PQA is dedicated to improving safe, effective and appropriate medication use and addressing issues that impact a person’s ability to access and use medications.
The Medicare Part D medication therapy management (MTM) program aims to optimize therapeutic outcomes and reduce the risk of adverse events and associated costs by identifying and addressing medication therapy problems. There are specific eligibility criteria for Medicare beneficiaries to take advantage of these services. However, a significant portion of those eligible do not choose to participate in the program.
Join us as we head to the Sunshine State for the 2025 PQA Annual Meeting, May 19-21! Meeting registration and hotel reservations are now open—don’t miss your chance to participate! Make your plans to join us and other quality professionals in Tampa at the primer event for quality medication use.
PQA and research partners at the University of Arizona, the University of Health Sciences and Pharmacy in St. Louis, and Merck & Co. recently conducted patient interviews to explore patients’ perceptions of their experience with comprehensive medication reviews (CMR).
PQA has published a new report that summarizes the conversations from PQA Convenes: Quality Medication Use in Rare Disease, held on November 7, which brought together health care quality experts, rare disease leaders and individuals with lived experience to discuss what constitutes high-quality rare disease medication use.
Barriers to medication access are a public health issue that affect adherence and patient outcomes. PQA emphasizes the pharmacist’s role in medication access and developed the Medication Access Patient Journey (MAPJ) conceptual framework that defines a patient’s medication access journey and characterizes barriers frequently encountered while seeking medication access. This framework highlights seven steps, or nodes, of the patient's journey to medication access: perceived need, help seeking, encounter, prescribing, prescription adjudication, prescription dispensing, and adherence.
Only about five percent of rare diseases have treatments that are approved by the FDA, but the situation is improving. Today, drugs designed to treat rare diseases make up half of new drug approvals each year.
PQA has published a new report detailing technical recommendations for advancing health equity with PQA quality measures. Developed by the PQA Health Equity Technical Expert Panel (TEP), it provides key recommendations for PQA measure testing and use in quality programs.
PQA has appointed individuals from member organizations to serve on the 2025 PQA Measure Update Panel (MUP) and Quality Metrics Expert Panel (QMEP).
PQA has published more than 60 blogs this year, providing insights and updates on our work to improve medication use quality. As we close out 2024, here’s a look back at the top five blogs of the year.
This guest blog is one in a series by sponsors of the 2024 PQA Leadership Summit on how MedWatchers is using AI to empower better patient care. PQA does not endorse, recommend or favor any product, service or organization that is a sponsor.
This guest blog is one in a series by sponsors of the 2024 PQA Leadership Summit on why a large diverse clinical pharmacy network is so important to payer performance. PQA does not endorse, recommend or favor any product, service or organization that is a sponsor.
As a PQA MPH Practicum Program student this summer, I collaborated with the Performance Measurement and Research Team to learn about PQA’s various frameworks and initiatives. As a dual-degree student pursuing my Doctor of Pharmacy (PharmD) and Master of Public Health (MPH), I found my background and interests to be greatly aligned with PQA. The practicum experience enriched my understanding of measure development through its iterative lifecycle and illuminated how PQA’s efforts positively impact pharmacy services like medication therapy management (MTM).
PQA is now is accepting self-nominations for the 2025 PQA Quality Shadowing Program. This program provides individuals from diverse groups the opportunity to observe PQA’s Quality Metrics Expert Panel or the Measure Update Panel.
PQA members gathered in Arlington, Va., November 7-8, 2024, for the 2024 PQA Leadership Summit. The summit focused on PQA's recent and ongoing work to develop standard pharmacy quality measures.
PQA members and health quality professionals gathered in Arlington, Va., on November 7 for PQA Convenes: Quality Medication Use in Rare Disease. This half-day event brought together health care quality experts, rare disease leaders and individuals with lived experience to discuss what constitutes high-quality rare disease medication use.
We are excited to host members next week at the 2024 PQA Leadership Summit and PQA Convenes: Quality Medication Use in Rare Disease at the Renaissance Arlington Capital View Hotel in Arlington, Va. This year's summit will focus on PQA's recent and ongoing work to develop standard pharmacy quality measures.
